Emilie A. Chapeau - Concepedia

Author

Emilie A. Chapeau

Novartis (Switzerland)ORCID

Also Known As

Emilie A. Chapeau, Emilie Anne Chapeau, Emilie Chapeau

Publications

614

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research

About

Emilie A. Chapeau is an author at Novartis (Switzerland) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	98
2	Natural Sciences	3	3	88
3	Biochemistry	3	3	88
4	Biomolecular Engineering	1	1	21
5	Cell Biology	1	1	10

Emilie A. Chapeau

Publications

606

Citations

H-Index

Page 1

	Year	Citations
Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism Eric Erquan Zhang, Emilie A. Chapeau, Kazuki Hagihara, Proceedings of the National Academy of Sciences	2004	258
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, Nature Cancer	2024	104
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Cancer Research	2018	85
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf <sup>−/−</sup> mouse model Emilie A. Chapeau, Agnieszka Gembarska, Éric Durand, Proceedings of the National Academy of Sciences	2017	61
The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition Pascal Furet, Vincent Bordas, Mickaël Le Douget, ChemMedChem Drug TargetYap-tead InteractionDirect CompetitionMolecular BiologyChemical Biology	2022	42
Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations Tobias Schmelzle, Emilie A. Chapeau, Daniel Bauer, Cancer Research PharmacotherapyAbstract Lb319ProteomicsRadiation OncologyNovel Therapy	2023	25
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors Holger Sellner, Emilie A. Chapeau, Pascal Furet, ChemMedChem Drug TargetNanotherapeuticsPeptide SciencePharmacotherapyPharmaceutical Chemistry	2023	21
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression Emilie A. Chapeau, Emeline Mandon, Jason Gill, PLoS ONE Hematological MalignancyKnockout MouseTransgene ExpressionMalignant Blood DisorderImmunology	2019	10

Page 1